Saturday, October 29, 2016 10:00:59 AM
the good Dr mentioned they were good on cash at one of the two investment seminars in a Q&A after his presentation. It was 2nd half of this year anyway..
look..i don't understand how $9,000,000 may accomplish what it takes BP TRILLIONS to fail..but I think it's because OUR DRUG ACTUALLY WORKS..
People get better and stay better..and therefor OTHER PEOPLE FUND TRIALS.
So..normally a small Co. that has engaged with a 60 BILLION (well regarded) goliath has accomplished much. A company that has taken a new Pharma through Safety Phase 2 succesfully..has accomplished MUCH..That they have a drug which shows Pharmacokinetics and Efficacy to Dosage Changes in an incurable disease patient population, they have accomplished much..when their safety profile includes more ancedotal positives! than negative side effects..they are deemed to have accomplished much!
IT appears ONLY in the REALM of the Netherworld where the forces of darkness and doubt have aligned to DELAY and DESTROY TRUTH that these
accomplishments of MUCH are questioned and thrown to the garbage can, because the Co. won't give out an Outstanding Share Count to an individual investor.
oh my..Anavex won't say how many rolls of toilet paper thay go through in a month either! SELL!
look..i don't understand how $9,000,000 may accomplish what it takes BP TRILLIONS to fail..but I think it's because OUR DRUG ACTUALLY WORKS..
People get better and stay better..and therefor OTHER PEOPLE FUND TRIALS.
So..normally a small Co. that has engaged with a 60 BILLION (well regarded) goliath has accomplished much. A company that has taken a new Pharma through Safety Phase 2 succesfully..has accomplished MUCH..That they have a drug which shows Pharmacokinetics and Efficacy to Dosage Changes in an incurable disease patient population, they have accomplished much..when their safety profile includes more ancedotal positives! than negative side effects..they are deemed to have accomplished much!
IT appears ONLY in the REALM of the Netherworld where the forces of darkness and doubt have aligned to DELAY and DESTROY TRUTH that these
accomplishments of MUCH are questioned and thrown to the garbage can, because the Co. won't give out an Outstanding Share Count to an individual investor.
oh my..Anavex won't say how many rolls of toilet paper thay go through in a month either! SELL!
Recent AVXL News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
